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THE EFFECT OF TAMOXIFEN TREATMENT ON LDL SUB-
FRACTION PARTICLE SIZE IN BREAST CANCER PATIENTS.
N. I. Ntukidem, MD, P. Blanche, PhD, L. Li, PhD, R. M. Krauss,
MD, T. C. Skaar, PhD, Z. Desta, PhD, A. M. Storniolo, MD, V.
Stearns, MD, D. F. Hayes, MD, D. A. Flockhart, MD, PhD, Indiana
University, University of California, University of Michigan, India-
napolis, IN.
BACKGROUND: Small dense LDL particles are associated with
increased atherogenicity. We examined the effect of tamoxifen treat-
ment on LDL subfraction particle size.
METHODS: 49 breast cancer patients were prospectively fol-
lowed on adjuvant tamoxifen treatment. LDL peak particle size
measurements were performed on plasma using non-denaturing poly-
acrylamide gradient gel electrophoresis and standardized conditions
at baseline and after 4 months of tamoxifen treatment. Genetic
variants in the estrogen receptors  [rs#2234693 (PvuII) and
rs#9340799 (XbaI)] and  [rs#1256049 (ESR2-01) and rs#4986938
(ESR-02)] were analyzed.
RESULTS: The mean LDL particle diameter were 268.09 and
266.82 Å at baseline and after 4 months of tamoxifen treatment
respectively (p0.088). 38 (77%) of the women had LDL Phenotype
A at baseline compared to 35 (71%) after 4 months of tamoxifen
treatment (P0.9). The small dense LDL subfraction (phenotype B)
was present in 9 (18%) of the women at baseline and 6 (12%) after
4 months of tamoxifen therapy. The baseline LDL major size was not
significantly different in pre-and postmenopausal women (270.6 vs.
266.5, P0.15). The effect of tamoxifen on lipid particle size was
similar when analyzed by menopausal status (P0.24). We found no
association between estrogen receptor genotypes and LDL subfrac-
tions.
CONCLUSIONS: Tamoxifen treatment does not alter LDL sub-
fraction particle size in breast cancer patients.
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FUNCTIONALLY SIGNIFICANT VARIANTS OF CYP2J2
AND EPHX2 ARE NOT ASSOCIATED WITH HYPERTENSION.
D. L. Kroetz, PhD, Z. Yu, PhD, T. Y. Langaee, PhD, J. A. Johnson,
PharmD, University of California San Francisco, University of Flor-
ida, San Francisco, CA.
BACKGROUND/AIMS: CYP2J2 catalyzes the formation of ep-
oxyeicosatrienoic acids (EETs) with antihypertensive properties. The
effects of the EETs are attenuated through hydrolysis by soluble
epoxide hydrolase (sEH encoded by EPHX2). This study examined
whether genetic variants of CYP2J2 and EPHX2 with decreased
function/expression in vitro are associated with hypertension (HTN).
METHODS: Hypertensive (HT; n199) and normotensive (NT;
n125) African Americans (AA) and HT (n187) and NT (n175)
Caucasians (CA) between 35-65 years of age were studied. NT had
BP  140/90 mmHg and no primary family history of HTN. The
following variants were genotyped by pyrosequencing: in AA the
372CT (Arg103Cys) and 925GA (Arg287Gln) variants of
EPHX2, and in AA and CA the CYP2J27 promoter allele. Minor
allele frequencies (MAFs) were compared between NT and HT using
a Chi-square test and differences in blood pressure between genotype
groups was compared with a t-test.
RESULTS: The MAF (see Table) for the EPHX2 and CYP2J2
variants were similar in NT and HT. DBP and SBP were not asso-
ciated with the EPHX2 or CYP2J2 genotypes or EPHX2 diplotypes.
EPHX2 EPHX2
372CT 925GA CYP2J27
NT AA 11% 9.2% 12%
HT AA 9.6% 8.7% 12%
NT CA 8.6%
HT CA 8.8%
CONCLUSIONS: Functionally significant genetic variants of
CYP2J2 and EPHX2 are not associated with HTN in AA and CA. The
importance of these variants in the progression of cardiac endpoints
associated with HTN is being investigated. Supported by NIH grants
HL53994 and HL64691.
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GENOTYPE FREQUENCIES FOR TEN POLYMORPHISMS
OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BE-
TWEEN HEALTHY FRENCH-CANADIANS AND OTHER ETH-
NIC GROUPS. M. Zakrzewski-Jakubiak, MSc, S. de Denus, MSc, M.
Dube´, PhD, F. Be´langer, MSc, M. White, MD, J. Turgeon, PhD, Uni-
versity of Montreal, Institut de Cardiologie de Montreal, Montreal,
PQ, Canada.
BACKGROUND/AIMS: Differences exist in frequencies of cer-
tain genotypes within different populations. We analysed the poly-
morphism frequency of ten polymorphisms of the RAAS in our
population and compared them to other ethnic groups.
METHODS: This is an observational study performed on 18 to 25
years old 200 healthy males of French-Canadian origin. The Gen
Elute Blood Genomic DNA kit (Sigma PC# NA2020) was used to
extract DNA. The studied polymorphisms were: ACE I/D, ATR1
A1166C, AGT M235T, AGT T174M, CYP11B2 T-344C, -adducin
G460W, beta-2 adrenergic receptor Q27E, bradykinin 2R 9/-9,
eNOS T-786C and eNOS E298D. They were analysed by the stan-
dard PCR/enzymatic digestion/electrophoresis method.
RESULTS: All polymorphisms tested were in Hardy-Weinberg
equilibrium. When compared to other ethnic groups, our population’s
genotype frequencies differed from the Asian and the African-
American populations with respect to every polymorphism, except
for the bradykinin 2R gene (data was unavailable) and differed from
the African population with respect to the polymorphism of ACE,
AGT235, AGT174 and CYP11B2. When compared with other Cau-
casian populations, we obtained different genotype frequencies for
the ATR1, AGT235, beta-2 adrenergic receptor, eNOS-786 and
eNOS298 genes.
CONCLUSION: Our study depicts the genetic profile of ten
polymorphisms of the RAAS in French-Canadian healthy man. We
noted differences in that profile when compared to Africans, African-
Americans, Asians and other Caucasians.
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THE EFFECTS OF FOLATE SUPPLEMENTATION ON HU-
MAN CYP2C9 TRANSACTIVATION. H. G. Xie, MD, PhD, M.
Muszkat, MD, C. M. Stein, MD, R. B. Kim, MD, Vanderbilt Uni-
versity School of Medicine, Hadassah University Hospital, Nashville,
TN.
BACKGROUND/AIMS: Folic acid (FA) supplementation can
increase the metabolism of phenytoin and warfarin, both of which are
CYP2C9 substrates, but the mechanisms underlying this are un-
known. This study examined the hypothesis that FA affects transac-
tivation of a defined core promoter in human CYP2C9 gene, in which
CAR, PXR, HNF1, and HNF4 binding sites exist.
METHODS: CYP2C9-luciferase reporter constructs (-3kb) were
transfected into HepG2 cells, and human CAR, PXR, HNF1, and
HNF4 were co-transfected either alone or in combination. The
transfected cells were treated with or without FA (100M), and the
cells co-transfected with PXR were simultaneously treated with ri-
fampin (Rif, 10M), followed by dual luciferase assays. Data were
expressed as fold activation versus vector control.
RESULTS: Compared with each of the vehicle controls, FA
treatment did not significantly affect luciferase activities (FA vs
DMSO: 1.9  0.6 vs 1.8  0.6 for CAR; 12.9  4.2 vs 12.5  3.8
for CAR  HNF1; 14.9  7.8 vs 15.4  9.3 for CAR  HNF4;
1.3  0.3 vs 1.3  0.4 for PXR/Rif; 9.4  2.8 vs 8.9  2.6 for
PXR/Rif  HNF1; 3.1  1.5 vs 3.1  1.8 for PXR/Rif  HNF4;
all P  0.05, n  6 each).
CONCLUSIONS: In transfected HepG2 cells, acute administra-
tion of folic acid has no effect on CYP2C9 transcriptional activity,
regardless of co-transfection with CAR, PXR, HNF1, and HNF4,
alone or in combination. The effect of folic acid on the metabolism of
CYP2C9 substrates is not mediated by alteration of transcription by
key nuclear receptors.
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